EISAI CO
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1941-12-06
- Employees
- 11K
- Market Cap
- $12B
- Website
- http://www.eisai.co.jp
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
Phase 2
Completed
- Conditions
- Peripheral T-cell LymphomaCutaneous T-cell Lymphoma
- Interventions
- First Posted Date
- 2016-02-08
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT02676778
- Locations
- 🇯🇵
Eisai Trial Site #1, Okayama, Japan
🇯🇵Eisai Trial Site #2, Suita, Osaka, Japan
A Study of Donepezil Hydrochloride in Patients With Dementia Associated With Cerebrovascular Disease
Phase 4
Completed
- Conditions
- Dementia Associated With Cerebrovascular Disease
- Interventions
- First Posted Date
- 2016-01-21
- Last Posted Date
- 2020-01-10
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 302
- Registration Number
- NCT02660983
Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy
- First Posted Date
- 2015-10-19
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 29
- Registration Number
- NCT02579616
Investigation of the Safety and Efficacy of Long Term Administration of Eszopiclone in Insomnia Patients
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 438
- Registration Number
- NCT02455271
Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)
- First Posted Date
- 2015-05-27
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT02454478
- Locations
- 🇯🇵
Eisai Trial Site #1, Tokyo, Japan
🇯🇵Eisai Trial Site #2, Tokyo, Japan
Investigation of the Safety and Efficacy of Eszopiclone in Insomnia Patients
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 4876
- Registration Number
- NCT02452684
Post-marketing Surveillance of Donepezil Hydrochloride - Investigation of Long Term Safety and Efficacy of Aricept as Well as Its Proper Use Information in Patients With Dementia With Lewy Bodies (DLB).
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2018-07-11
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 591
- Registration Number
- NCT02448784
Post-marketing Surveillance of Lenvatinib Mesylate (Lenvima Capsule) in Patients With Unresectable Thyroid Cancer (Study LEN01T)
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 629
- Registration Number
- NCT02430714
An Open-label Extension Study to Evaluate the Safety and Tolerability of Perampanel (E2007) Administered as an Adjunctive Therapy in Epilepsy Subjects
- First Posted Date
- 2015-04-28
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 7
- Registration Number
- NCT02427607
Rabeprazole Specific Clinical Experience Investigation for the Long-term Combination Therapy With Low-dose Aspirin
Completed
- Conditions
- Gastric UlcerDuodenal Ulcer
- Interventions
- Other: No Intervention
- First Posted Date
- 2015-04-22
- Last Posted Date
- 2018-08-28
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 1568
- Registration Number
- NCT02423187